Skip to main content
Erschienen in: Hepatology International 2/2010

01.06.2010 | Case Report

Acute hepatitis B despite a previous high titer of anti-HBs

verfasst von: Resat Ozaras, Cem Ar, Seniz Ongoren, Bilgul Mete, Fehmi Tabak, Ali Mert, Recep Ozturk

Erschienen in: Hepatology International | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Loss of HBsAg and development of surface and core antibodies represent clinical cure. However, recent evidence suggests that hepatitis B virus (HBV) persists in a latent state even in those with mounted protective antibodies. After significant immunosuppression, anti-HBs may decrease and HBsAg may reappear (reverse seroconversion). Reverse seroconversion of HBV has been observed in association with hematopoietic stem cell transplantation, renal transplantation, intensive chemotherapy, human immunodeficiency infection, or rituximab usage.

Case report

We present here a case study of a patient with a previous high titer of anti-HBs who later developed HBV reactivation following intensive chemotherapy for leukemia.

Conclusion

We conclude that in immunosuppressed patients with a history of HBV infection may carry a risk for reverse seroconversion and monitoring anti-HBs levels may help recognising this risk.
Literatur
1.
Zurück zum Zitat Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230–239CrossRefPubMed Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230–239CrossRefPubMed
2.
Zurück zum Zitat Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104–1108CrossRefPubMed Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104–1108CrossRefPubMed
3.
Zurück zum Zitat Goyama S, Kanda Y, Nannya Y, Kawazu M, Takeshita M, Niino M, et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002;43:2159–2163CrossRefPubMed Goyama S, Kanda Y, Nannya Y, Kawazu M, Takeshita M, Niino M, et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002;43:2159–2163CrossRefPubMed
4.
Zurück zum Zitat Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1988;94:151–156PubMed Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1988;94:151–156PubMed
5.
Zurück zum Zitat Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207–208PubMed Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207–208PubMed
6.
Zurück zum Zitat Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627–629CrossRefPubMed Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627–629CrossRefPubMed
7.
Zurück zum Zitat Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007;21:771–774CrossRefPubMed Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007;21:771–774CrossRefPubMed
8.
Zurück zum Zitat Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616–619CrossRefPubMed Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616–619CrossRefPubMed
9.
Zurück zum Zitat Orlando R, Tosone G, Tiseo D, Piazza M, Portella G, Ciancia R, et al. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients? Infection 2006;34:282–284CrossRefPubMed Orlando R, Tosone G, Tiseo D, Piazza M, Portella G, Ciancia R, et al. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients? Infection 2006;34:282–284CrossRefPubMed
10.
Zurück zum Zitat Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:463–468CrossRefPubMed Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:463–468CrossRefPubMed
11.
Zurück zum Zitat van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 1996;87:818–826PubMed van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 1996;87:818–826PubMed
12.
Zurück zum Zitat Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005;41:1277–1282CrossRefPubMed Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005;41:1277–1282CrossRefPubMed
13.
Zurück zum Zitat Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007;14:478–483CrossRefPubMed Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007;14:478–483CrossRefPubMed
Metadaten
Titel
Acute hepatitis B despite a previous high titer of anti-HBs
verfasst von
Resat Ozaras
Cem Ar
Seniz Ongoren
Bilgul Mete
Fehmi Tabak
Ali Mert
Recep Ozturk
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2010
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9177-3

Weitere Artikel der Ausgabe 2/2010

Hepatology International 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.